| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
The primary biological target of amylin is the amylin (AMY) receptor, which is formed by the calcitonin receptor (CTR) core with receptor activity-modifying proteins (RAMPs). It acts as a regulatory peptide that suppresses glucagon release.
|
|---|---|
| ln Vitro |
IAPP (amylin) and TFA from felines can combine to form pancreatic islet amyloid deposits [1]. Cats' gastrointestinal tracts express amylin (IAPP), a feline TFA[1].
In isolated pancreatic islets or beta-cell lines, feline amylin inhibits both insulin and glucagon secretion in a concentration-dependent manner. It acts as a paracrine regulator within the islets, modulating the secretory activity of both alpha-cells (glucagon) and beta-cells. |
| ln Vivo |
In animal models of glucose homeostasis, amylin administration slows gastric emptying, suppresses postprandial glucagon secretion, and promotes satiety. These effects collectively lower postprandial blood glucose excursions. Feline amylin is used as a research tool to study IAPP biology.
|
| Enzyme Assay |
In vitro, the biological activity is assessed using isolated rat pancreatic islets or mouse islets. Islets are incubated with glucose and varying concentrations of the peptide. Insulin and glucagon levels in the supernatant are measured by ELISA or RIA.
|
| Cell Assay |
Pancreatic beta-cell lines (e.g., INS-1 or MIN6) are treated with feline amylin to study its effects on insulin secretion and signaling pathways. Cultured islets are used for paracrine signaling studies. After stimulation, hormone release into the medium is quantified.
|
| Animal Protocol |
Rodent models of metabolic syndrome or diabetes are administered feline amylin via intraperitoneal or subcutaneous injection. Blood glucose levels are monitored over time, and plasma samples are collected for insulin and glucagon measurement. Gastric emptying rate may also be assessed.
|
| ADME/Pharmacokinetics |
Amylin peptides have a short plasma half-life (approximately 10-15 minutes) due to rapid renal clearance and enzymatic degradation. They are primarily cleared by the kidneys. This limits their therapeutic utility and necessitates continuous infusion or long-acting analogs.
|
| Toxicity/Toxicokinetics |
In research settings, acute administration shows no significant toxicity. However, in humans, accumulation of human IAPP in pancreatic islets leads to amyloid deposits, which are associated with beta-cell dysfunction and type 2 diabetes. Feline amylin is less amyloidogenic.
|
| References | |
| Additional Infomation |
This feline-derived peptide is used as a research tool to study islet amyloid polypeptide biology. It is not approved for clinical use. Pramlintide, a synthetic analog of human amylin, is FDA-approved as an adjunct therapy for type 1 and type 2 diabetes.
|
| Molecular Formula |
C167H271F3N52O56S2
|
|---|---|
| Molecular Weight |
4024.47
|
| Related CAS # |
Amylin (IAPP), feline
|
| Appearance |
Solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.2485 mL | 1.2424 mL | 2.4848 mL | |
| 5 mM | 0.0497 mL | 0.2485 mL | 0.4970 mL | |
| 10 mM | 0.0248 mL | 0.1242 mL | 0.2485 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
